首页> 外文期刊>Annals of Surgery >Recombinant human thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice
【24h】

Recombinant human thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice

机译:重组人血栓调节蛋白抑制小鼠氯化钙诱导的实验性腹主动脉瘤

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE:: To investigate whether recombinant thrombomodulin containing all the extracellular domains (rTMD123) has therapeutic potential against aneurysm development. SUMMARY BACKGROUND DATA:: The pathogenesis of abdominal aortic aneurysm (AAA) is characterized by chronic inflammation and proteolytic degradation of extracellular matrix. Thrombomodulin, a transmembrane glycoprotein, exerts anti-inflammatory activities such as inhibition of cytokine production and sequestration of proinflammatory high-mobility group box 1 (HMGB1) to prevent it from engaging the receptor for advanced glycation end product (RAGE) that may sustain inflammation and tissue damage. METHODS:: The in vivo effects of treatment and posttreatment with rTMD123 on aortic dilatation were measured using the CaCl2-induced AAA model in mice. RESULTS:: Characterization of the CaCl2-induced model revealed that HMGB1 and RAGE, both localized mainly to macrophages, were persistently upregulated during a 28-day period of AAA development. In vitro, rTMD123-HMGB1 interaction prevented HMGB1 binding to macrophages, thereby prohibiting activation of HMGB1-RAGE signaling in macrophages. In vivo, short-term treatment with rTMD123 upon AAA induction suppressed the levels of proinflammatory cytokines, HMGB1, and RAGE in the aortic tissue; reduced the infiltrating macrophage number; and finally attenuated matrix metalloproteinase production, extracellular matrix destruction, and AAA formation without disturbing vascular calcification. Consistently, posttreatment with rTMD123 seven days after AAA induction alleviated vascular inflammation and retarded AAA progression. CONCLUSIONS:: These data suggest that rTMD123 confers protection against AAA development. The mechanism of action may be associated with reduction of proinflammatory mediators, blockade of macrophage recruitment, and suppression of HMGB1-RAGE signaling involved in aneurysm formation and downstream macrophage activation.
机译:目的::研究包含所有细胞外结构域(rTMD123)的重组血栓调节蛋白是否具有治疗动脉瘤发展的潜力。摘要背景数据:腹主动脉瘤(AAA)的发病机制的特征是慢性炎症和细胞外基质的蛋白水解降解。血栓调节蛋白是一种跨膜糖蛋白,具有抗炎活性,例如抑制细胞因子的产生和螯合促炎性高迁移率族盒1(HMGB1),以防止其与可能持续维持炎症状态的晚期糖基化终产物(RAGE)受体结合。软组织挫伤。方法:使用CaCl2诱导的AAA模型在小鼠中测量rTMD123处理和后处理对主动脉扩张的体内效应。结果:CaCl2诱导的模型的特征表明,HMGB1和RAGE主要位于巨噬细胞,在AAA发育的28天期间持续上调。在体外,rTMD123-HMGB1相互作用阻止HMGB1与巨噬细胞结合,从而阻止巨噬细胞中HMGB1-RAGE信号的激活。在体内,AAA诱导后短期用rTMD123治疗可抑制主动脉组织中促炎细胞因子,HMGB1和RAGE的水平。减少浸润的巨噬细胞数量;并最终减弱了基质金属蛋白酶的产生,细胞外基质的破坏和AAA的形成,而不会干扰血管钙化。一致地,AAA诱导后7天用rTMD123进行后处理可减轻血管炎症并延缓AAA进展。结论:这些数据表明rTMD123赋予了针对AAA发育的保护作用。作用机制可能与减少促炎性介质,阻断巨噬细胞募集以及抑制与动脉瘤形成和下游巨噬细胞活化有关的HMGB1-RAGE信号传导有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号